Security
Immatics N.V. Warrants · IMTXW
IMTXWNASDAQWarrantHistorical · closed Jun 30, 2025CIK 1809196Updated Nov 20, 2026
IMTXW price & chart
This listing closed Jun 30, 2025. Live provider charts are shown only for current listings.
Current security: IMTX
About the company
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · EURSource
Source
cash flow · annual statements
| Line item | Q4 2024 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Profit or LossEUR | — | -70,348,000Source | -17,992,000Source | -24,610,000Source | -13,980,000Source | -26,534,000Source | -21,326,000Source | -196,447,000Source | 15,218,000Source | -96,994,000Source | 37,514,000Source |
| Additional Financial Items | |||||||||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | — | — | — | — | — | — | — | -242,000Source | -1,764,000Source | -2,982,000Source | -429,000Source |
| GeneralAndAdministrativeExpenseEUR | — | 12,780,000Source | 10,128,000Source | 9,358,000Source | 8,683,000Source | 8,271,000Source | 10,076,000Source | 51,184,000Source | 46,449,000Source | 38,198,000Source | 36,124,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | — | 946,000Source | 886,000Source | 290,000Source | 695,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | — | 26,817,000Source | 15,605,000Source | 10,167,000Source | 1,649,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | 2,959,000Source | 2,012,000Source | 3,849,000Source | 2,843,000Source |
| ProceedsFromIssuingSharesEUR | — | — | — | — | — | — | — | 107,310,000Source | 343,010,000Source | 90,404,000Source | 134,484,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodEUR | — | — | — | — | — | — | — | 549,859,000Source | 314,440,000Source | 414,744,000Source | 12,695,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | — | — | 2,000Source | 150,000Source | 52,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | — | 247,000Source | 208,000Source | 158,000Source | 477,000Source |
income statement · annual statements
| Line item | Q4 2024 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Financial Items | |||||||||||
| ApplicableTaxRatenumber | — | 0.3Source | 0.3Source | 0.3Source | 0.29Source | 0.29Source | 0.29Source | 0.31Source | 0.3Source | 0.3Source | 0.3Source |
| BasicEarningsLossPerShareEUR/shares | — | -0.58Source | -0.17Source | -0.32Source | -0.22Source | -0.42Source | — | -1.61Source | 0.14Source | -1.2Source | 0.56Source |
| CurrentTaxExpenseIncomeEUR | — | 0Source | 170,000Source | — | — | — | — | 9,000Source | 7,790,000Source | 0Source | -12,774,000Source |
| DeferredTaxExpenseIncomeEUR | — | -1,001,000Source | -30,000Source | — | — | — | — | -1,998,000Source | -1,662,000Source | — | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | — | — | — | — | — | — | — | 100,000Source | — | — | — |
| DepreciationRightofuseAssetsEUR | — | — | — | — | — | — | — | 3,231,000Source | 3,417,000Source | 3,723,000Source | -3,620,000Source |
| DilutedEarningsLossPerShareEUR/shares | — | -0.58Source | -0.17Source | -0.32Source | -0.22Source | -0.42Source | — | -1.61Source | 0.14Source | -1.2Source | 0.55Source |
| EmployeeBenefitsExpenseEUR | — | — | — | — | — | — | — | 103,073,000Source | 89,342,000Source | 76,325,000Source | -73,205,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | 4,141,000Source | 4,308,000Source | 5,513,000Source | -5,560,000Source | 7,965,000Source | 8,691,000Source | 15,015,000Source | 17,642,000Source | 20,705,000Source | -22,570,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR | — | — | — | — | — | — | — | 109,000Source | 85,000Source | 86,000Source | — |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | — | — | — | — | — | — | — | — | — | 1,548,000Source | -190,000Source |
| FinanceCostsEUR | — | 22,776,000Source | 305,000Source | 1,144,000Source | 407,000Source | 629,000Source | 2,164,000Source | 36,666,000Source | 1,321,000Source | -7,040,000Source | 8,279,000Source |
| FinanceIncomeEUR | — | 4,421,000Source | 9,665,000Source | 3,954,000Source | 7,015,000Source | 213,000Source | 437,000Source | 18,516,000Source | 44,018,000Source | 13,850,000Source | 9,416,000Source |
| GeneralAndAdministrativeExpenseEUR | — | 12,780,000Source | 10,128,000Source | 9,358,000Source | 8,683,000Source | 8,271,000Source | 10,076,000Source | 51,184,000Source | 46,449,000Source | 38,198,000Source | 36,124,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | — | -1,001,000Source | 140,000Source | 0Source | 1,145,000Source | 0Source | 0Source | -1,989,000Source | 6,128,000Source | 0Source | 4,522,000Source |
| InterestExpenseEUR | — | 244,000Source | 226,000Source | 206,000Source | 376,000Source | 140,000Source | 81,000Source | 946,000Source | 886,000Source | 831,000Source | 1,038,000Source |
| OtherEmployeeExpenseEUR | — | — | — | — | — | — | — | 400,000Source | 300,000Source | 200,000Source | 100,000Source |
| OtherFinanceCostEUR | — | 22,776,000Source | 305,000Source | 1,144,000Source | 407,000Source | — | — | 36,666,000Source | 1,321,000Source | 7,040,000Source | 8,279,000Source |
| OtherIncomeEUR | — | 22,000Source | 25,000Source | 6,000Source | 27,000Source | 26,000Source | 86,000Source | 4,734,000Source | 78,000Source | 1,139,000Source | 26,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansEUR | — | — | — | — | — | — | — | 2,200,000Source | 1,600,000Source | 500,000Source | 900,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | — | — | -17,992,000Source | — | — | -26,534,000Source | -21,043,000Source | — | — | — | 37,514,000Source |
| ProfitLossBeforeTaxEUR | — | -71,349,000Source | -17,852,000Source | -24,610,000Source | -12,835,000Source | -26,534,000Source | -21,326,000Source | -198,436,000Source | 21,346,000Source | -96,994,000Source | 42,036,000Source |
| ProfitLossFromOperatingActivitiesEUR | — | -53,127,000Source | -26,564,000Source | -14,315,000Source | -16,657,000Source | -23,396,000Source | -19,599,000Source | -182,016,000Source | -38,615,000Source | -101,725,000Source | 29,954,000Source |
| ResearchAndDevelopmentExpenseEUR | — | 45,106,000Source | 35,216,000Source | 27,317,000Source | 25,216,000Source | 20,340,000Source | 16,505,000Source | 183,832,000Source | 148,079,000Source | 118,663,000Source | 106,779,000Source |
| NetForeignExchangeLoss | — | — | — | — | — | —Source | —Source | — | — | — | — |
| ProfitLossAttributableToNoncontrollingInterests | — | — | — | — | — | — | —Source | — | — | — | — |
Filing attachments
imtx-ex99_1.htm · 6-K · 2026-11-10
Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended September 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros. All references in this interim report to “$,” and “U.S. dollars” mean U.S. dollars a…
Read attachment ↗imtx-ex99_2.htm · 6-K · 2026-11-10
Exhibit 99.2 PRESS RELEASE Immatics Announces Third Quarter 2026 Financial Results and Business Update • Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint • SUPRAME topline data disclosure remains expected in H1 2027, followed by BLA submission in 2027 • IMA203CD8 PRAME Cell Therapy: Updated Phase 1 data presented at ESMO Congress 2026 s…
Read attachment ↗d153472dex41.htm · 6-K · 2026-08-26
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES IMMATICS N.V. Number of Ordinary Shares: [_________] (subject to adjustment) Warrant No. [___] Date of Issuance: [___], 2026 (such date, the “Original Issue Date”) Immatics N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered as…
Read attachment ↗d153472dex991.htm · 6-K · 2026-08-26
Exhibit 99.1 PRESS RELEASE Immatics Announces $150 Million Underwritten Offering Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purch…
Read attachment ↗imtx-ex99_1.htm · 6-K · 2026-08-18
Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month period ended June 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros. All references in this interim report to “$,” and “U.S. dollars” mean U.S. dollars and all…
Read attachment ↗imtx-ex99_2.htm · 6-K · 2026-08-18
Exhibit 99.2 PRESS RELEASE Immatics Announces Second Quarter 2026 Financial Results and Business Update • Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeled • Company plans to proceed directly to a streamlined final analysis for the primary endp…
Read attachment ↗